logo
Plus   Neg
Share
Email

American Airlines Prices Common Stock, Convertible Notes Offerings

American Airlines Group Inc. (AAL) has priced its underwritten public offering of 74.1 million shares of its common stock, or approximately $1 billion of shares of its common stock, at a public offering price of $13.50 per share and its underwritten public offering of $1 billion aggregate principal amount of 6.50% convertible senior notes due 2025. The size of the common stock offering was increased from the previously announced $750 million of shares of common stock and the aggregate principal amount of the Convertible Notes Offering was increased from the previously announced $750 million.

The aggregate net proceeds to the company, after deducting underwriting discounts and other offering expenses, are expected to be approximately $1.936 billion. American Airlines Group expects to use the net proceeds for general corporate purposes and to enhance the liquidity position. Both of the common stock offering and the convertible notes offering are expected to close on June 25, 2020.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. auto safety regulator has opened an investigation into about 115,000 Tesla electric vehicles over a front suspension safety issue. The probe covers 2015 through 2017 Model S sedans and 2016 through 2017 Model X SUVs. The investigation comes after Tesla reportedly started a recall over the issue for vehicles in China. Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform
Follow RTT